Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coventry Shifting Medicare PBM Duties To Medco From CVS Caremark

Executive Summary

Medco credits its pharmacist-based therapeutic research center program with helping to attract new Medicare Part D business from Coventry Health Care

You may also be interested in...

Universal American, CVS/Caremark End Part D Alliance With Membership Split

CVS/Caremark will add Medicare members to its SilverScript stand-alone prescription drug plans in 2009 under an "amicable split" with Part D partner Universal American, announced Feb. 13

Warfarin Dosing Issues Emerge In Early Results From Medco/Mayo Research

Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its analyst day presentation Nov. 16

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts